

Mirakof[®]

Butamirate Citrate

COMPOSITION

Mirakof[®] SR Tablet: Each sustained release tablet contains Butamirate Citrate INN 50 mg.

Mirakof[®] Syrup: Each 5 ml syrup contains Butamirate Citrate INN 7.5 mg.

Mirakof[®] Paediatric Drops: Each ml drop contains Butamirate Citrate INN 5 mg.

PHARMACOLOGY

Butamirate Citrate acts directly on the brain's cough center to suppress cough. It is safe and non-sedating which is neither chemically nor pharmacologically related to opium alkaloids. It is rapidly and completely absorbed after oral administration. Maximum concentration is reached within 9 hours with sustained release tablet. Butamirate Citrate is extremely protein bound and plasma elimination half life is about 13 hours. The active metabolites of Butamirate Citrate have also antitussive action.

INDICATION

Mirakof[®] (Butamirate Citrate) is used to relieve dry (non-productive) cough. Dry cough may be caused by a recent viral infection. It is also used for pre- & post-operative cough sedation in patients who will undergo surgical procedures and bronchoscopy. It can be used in acute cough of any etiology, whooping cough and cough due to acute lower respiratory tract infections (tracheitis, laryngitis, bronchitis) etc.

DOSAGE AND ADMINISTRATION

Mirakof[®] SR Tablet:

Adult: 2-3 tablets daily at 8 to 12 hours intervals.

Adolescents over 12 years old: 1-2 tablets daily

Mirakof[®] Syrup:

Children (3-6 years): 5 ml 3 times daily,

Children (6-12 years): 10 ml 3 times daily,

Adolescent: 15 ml 3 times daily,

Adult: 15 ml 4 times daily.

Mirakof[®] Paediatric Drops:

Children (1-3 years): 0.75 ml 4 times daily.

Children (2 months-1 year): 0.50 ml 4 times daily.

USE IN PREGNANCY AND LACTATION

Butamirate Citrate should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution.

CONTRAINDICATION

Hypersensitivity to the active ingredient.

SIDE EFFECT

Tolerance of Butamirate Citrate is good. Adverse reactions such as rash, nausea and vertigo have been observed in a few rare cases, resolving after dose reduction or treatment withdrawal.

OVERDOSE

Accidental overdose with Butamirate Citrate can cause the following symptoms: drowsiness, nausea, vomiting, diarrhoea and hypotension. Standard emergency procedures should be followed: activated charcoal, saline laxatives and standard cardio-respiratory resuscitation.

STORAGE

Mirakof[®] SR Tablet & Syrup : Keep away from light and moisture, store below 30°C. Keep all the medicines out of the reach of children.

Mirakof[®] Paediatric Drops : Keep away from light and moisture, store below 25°C. Keep all the medicines out of the reach of children.

HOW SUPPLIED

Mirakof[®] SR Tablet: Each box contains 30 tablets in strip packs.

Mirakof[®] Syrup: Each box contains 100 ml syrup & a measuring cup.

Mirakof[®] Paediatric Drops: Each box contains 15 ml paediatric drops & a measuring dropper.